Stock Data
$3.08 (1.43%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Alnylam Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to the development and commercialization of innovative therapeutics based on RNA interference. The company's portfolio includes treatments for rare genetic conditions, such as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, among others. Alnylam is also exploring treatments for a variety of other diseases, including hemophilia, hypercholesterolemia, and Alzheimer’s disease. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has formed strategic partnerships with several leading pharmaceutical companies to advance its mission of transforming scientific discoveries into breakthrough therapies.
Alnylam swung to profitability and posted 67% revenue growth, but slashed full-year guidance as the blockbuster-track AMVUTTRA's initial surge from pent-up patient demand begins to normalize in the U.S. ATTR-CM market. The company now expects TTR revenues of $4.20 to $4.50 billion versus its prior $4.40 to $4.70 billion outlook, a reality check on how fast the cardiac amyloidosis franchise can actually grow.
78 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
